A simvastatin szerepe a diabeteses dyslipidaemia kezelésében

Translated title of the contribution: The role of simvastatin in the treatment of diabetic dyslipidaemia

Balogh Zoltán, G. Paragh

Research output: Contribution to journalArticle

Abstract

Patients with type 2 diabetes have markedly increased cardiovascular morbidity and mortality. Type 2 diabetes is typically associated with atherogenic dyslipidaemia, which is characterized by elevated triglycerides, low plasma levels of high-density lipoprotein cholesterol, and an increased ratio of small, dense low-density lipoprotein particles. Current treatment guidelines stress the importance of lipid-lowering therapy in reducing cardiovascular risk in diabetic patients. Statins currently represent the cornerstone of dyslipidaemia management, based on their ability to efficiently reduce cardiovascular risk through lowering low-density lipoprotein cholesterol. They have, however, a relatively modest effect on the components of atherogenic dyslipidaemia, since they reduce triglycerides by only 15 to 35% and elevate high-density lipoprotein cholesterol by less than 10%. This raises the need for combining statins with other lipid-lowering drugs (ezetimibe, nicotinic acid, fibrate) at an early stage of type 2 diabetes. Authors review the role of simvastatin monotherapy in the treatment of diabetic dyslipidaemia and summarize the results of studies on simvastatin as part of a combined lipid-lowering treatment.

Original languageHungarian
Pages (from-to)213-219
Number of pages7
JournalLege Artis Medicinae
Volume17
Issue number3
Publication statusPublished - Mar 2007

Fingerprint

Simvastatin
Dyslipidemias
Type 2 Diabetes Mellitus
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Lipids
HDL Cholesterol
Triglycerides
Fibric Acids
Niacin
Therapeutics
LDL Lipoproteins
LDL Cholesterol
Guidelines
Morbidity
Mortality
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A simvastatin szerepe a diabeteses dyslipidaemia kezelésében. / Zoltán, Balogh; Paragh, G.

In: Lege Artis Medicinae, Vol. 17, No. 3, 03.2007, p. 213-219.

Research output: Contribution to journalArticle

@article{b07f4e8c46f7491f9c04a993ed9c4468,
title = "A simvastatin szerepe a diabeteses dyslipidaemia kezel{\'e}s{\'e}ben",
abstract = "Patients with type 2 diabetes have markedly increased cardiovascular morbidity and mortality. Type 2 diabetes is typically associated with atherogenic dyslipidaemia, which is characterized by elevated triglycerides, low plasma levels of high-density lipoprotein cholesterol, and an increased ratio of small, dense low-density lipoprotein particles. Current treatment guidelines stress the importance of lipid-lowering therapy in reducing cardiovascular risk in diabetic patients. Statins currently represent the cornerstone of dyslipidaemia management, based on their ability to efficiently reduce cardiovascular risk through lowering low-density lipoprotein cholesterol. They have, however, a relatively modest effect on the components of atherogenic dyslipidaemia, since they reduce triglycerides by only 15 to 35{\%} and elevate high-density lipoprotein cholesterol by less than 10{\%}. This raises the need for combining statins with other lipid-lowering drugs (ezetimibe, nicotinic acid, fibrate) at an early stage of type 2 diabetes. Authors review the role of simvastatin monotherapy in the treatment of diabetic dyslipidaemia and summarize the results of studies on simvastatin as part of a combined lipid-lowering treatment.",
keywords = "Atherogenic dyslipidaemia, Combined lipid-lowering therapy, Simvastatin, Target lipid levels, Type 2 diabetes",
author = "Balogh Zolt{\'a}n and G. Paragh",
year = "2007",
month = "3",
language = "Hungarian",
volume = "17",
pages = "213--219",
journal = "Lege Artis Medicinae",
issn = "0866-4811",
publisher = "Literatura Medica Publishing House",
number = "3",

}

TY - JOUR

T1 - A simvastatin szerepe a diabeteses dyslipidaemia kezelésében

AU - Zoltán, Balogh

AU - Paragh, G.

PY - 2007/3

Y1 - 2007/3

N2 - Patients with type 2 diabetes have markedly increased cardiovascular morbidity and mortality. Type 2 diabetes is typically associated with atherogenic dyslipidaemia, which is characterized by elevated triglycerides, low plasma levels of high-density lipoprotein cholesterol, and an increased ratio of small, dense low-density lipoprotein particles. Current treatment guidelines stress the importance of lipid-lowering therapy in reducing cardiovascular risk in diabetic patients. Statins currently represent the cornerstone of dyslipidaemia management, based on their ability to efficiently reduce cardiovascular risk through lowering low-density lipoprotein cholesterol. They have, however, a relatively modest effect on the components of atherogenic dyslipidaemia, since they reduce triglycerides by only 15 to 35% and elevate high-density lipoprotein cholesterol by less than 10%. This raises the need for combining statins with other lipid-lowering drugs (ezetimibe, nicotinic acid, fibrate) at an early stage of type 2 diabetes. Authors review the role of simvastatin monotherapy in the treatment of diabetic dyslipidaemia and summarize the results of studies on simvastatin as part of a combined lipid-lowering treatment.

AB - Patients with type 2 diabetes have markedly increased cardiovascular morbidity and mortality. Type 2 diabetes is typically associated with atherogenic dyslipidaemia, which is characterized by elevated triglycerides, low plasma levels of high-density lipoprotein cholesterol, and an increased ratio of small, dense low-density lipoprotein particles. Current treatment guidelines stress the importance of lipid-lowering therapy in reducing cardiovascular risk in diabetic patients. Statins currently represent the cornerstone of dyslipidaemia management, based on their ability to efficiently reduce cardiovascular risk through lowering low-density lipoprotein cholesterol. They have, however, a relatively modest effect on the components of atherogenic dyslipidaemia, since they reduce triglycerides by only 15 to 35% and elevate high-density lipoprotein cholesterol by less than 10%. This raises the need for combining statins with other lipid-lowering drugs (ezetimibe, nicotinic acid, fibrate) at an early stage of type 2 diabetes. Authors review the role of simvastatin monotherapy in the treatment of diabetic dyslipidaemia and summarize the results of studies on simvastatin as part of a combined lipid-lowering treatment.

KW - Atherogenic dyslipidaemia

KW - Combined lipid-lowering therapy

KW - Simvastatin

KW - Target lipid levels

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=34247125685&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247125685&partnerID=8YFLogxK

M3 - Article

VL - 17

SP - 213

EP - 219

JO - Lege Artis Medicinae

JF - Lege Artis Medicinae

SN - 0866-4811

IS - 3

ER -